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Summary
The diagnosis of primary sclerosing cholangitis (PSC) is difficult due to the
lack of sensitive and specific biomarkers, as is the early diagnosis of
cholangiocarcinoma (CC), a complication of PSC. The aim of this study was
to identify specific serum miRNAs as diagnostic biomarkers for PSC and
CC. The levels of 667 miRNAs were evaluated in 90 human serum samples
(30 PSC, 30 CC and 30 control subjects) to identify disease-associated
candidate miRNAs (discovery phase). The deregulated miRNAs were
validated in an independent cohort of 140 samples [40 PSC, 40 CC, 20
primary biliary cirrhosis (PBC) and 40 controls]. Receiver operating
characteristic (ROC) curves were established and only miRNAs with an area
under the curve (AUC)> 070 were considered useful as biomarkers. In the
discovery phase we identified the following: 21 miRNAs expressed
differentially in PSC, 33 in CC and 26 in both in comparison to control
subjects as well as 24 miRNAs expressed differentially between PSC and CC.
After the validation phase, miR-200c was found to be expressed
differentially in PSC versus controls, whereas miR-483-5p and miR-194
showed deregulated expression in CC compared with controls. We also
demonstrate a difference in the expression of miR-222 and miR-483-5p in
CC versus PSC. Combination of these specific miRNAs further improved the
specificity and accuracy of diagnosis. This study provides a basis for the use
of miRNAs as biomarkers for the diagnosis of PSC and CC.
Keywords: biomarkers, cholangiocarcinoma, liver cancer, miRNAs, primary
sclerosing cholangitis
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Introduction
Primary sclerosing cholangitis (PSC) is a chronic choles-
tatic liver disease characterized by progressive inflamma-
tion and fibrosis of intrahepatic and extrahepatic bile
ducts. In a large proportion of patients, PSC progresses to
biliary cirrhosis and ultimately end-stage liver disease. The
diagnosis of PSC can be difficult because of the heterogene-
ous nature of PSC and the lack of a quantifiable diagnostic
test [1]. There is an enormous unmet need in PSC, and
among the autoimmune liver diseases it is the most enig-
matic and includes not only the inflammation and fibrosis
of bile ducts but, as discussed below, the appearance of the
fatal complication, cholangiocarcinoma (CC) [2–6]. CC is
a well-established and frequently fatal complication of PSC
[7], with the highest incidence within the first 25 years fol-
lowing the diagnosis of PSC [8–10].
Currently, CC is the second most common primary
hepatic malignancy, with recent epidemiological studies
suggesting an increasing prevalence in Western countries
[11]. CC is characterized by a poor prognosis with a
median survival of less than 24 months [12,13] and a poor
response to chemotherapy [14,15]. Surgical resection is the
only effective therapeutic option for CC, but is applicable
in fewer than 50% of cases because it is diagnosed mainly
at late stages. In early-stage CC, the 5-year survival after
radical surgery is greater than 80%. A number of different
risk factors have been identified for CC, with PSC being
the most commonly recognized one. However, due to the
lack of biomarkers or imaging features for the early detec-
tion of CC, current guidelines do not support routine sur-
veillance for CC.
The development of blood-based biomarker assays for
malignancies such as CC is critical, in particular for predis-
posing conditions such as PSC. Therefore, it is important
to identify effective surveillance strategies that will permit
early detection of CC or, better yet, premalignant lesions in
patients at increased risk. Several tumour markers, such as
carcinoembryonic antigen (CEA) and carbohydrate antigen
(CA 19-9), have been used to aid diagnosis of CC; however,
these markers are not specific and have not been shown to
be effective for early detection of CC in asymptomatic PSC
patients [14,16–23]. Thus, there is an obvious need for
accurate non-invasive serum markers for CC.
MicroRNAs (miRNAs) are endogenous non-coding
RNAs involved in post-transcriptional gene regulation
through base pairing to partially complementary sites
located in the 30-UTR of coding RNA [24]. There is an
enormous interest in developing newer diagnostic technol-
ogy and, in particular, using miRNAs to understand auto-
immune and chronic inflammatory disorders more clearly
[25,26].
Many miRNAs have been implicated in the control of
various disease states as well as all aspects of normal physi-
ology, including acting as tumour suppressor genes or
oncogenes. Because miRNAs are protected from RNases
and remain stable in plasma and serum [27], they hold
potential as biomarkers for early cancer detection [28,29].
Recent studies on human CC cell lines and tissues con-
cluded that miRNA expression is markedly different in nor-
mal cholangiocytes compared with malignant ones [30]. In
this study, we aimed to determine the diagnostic utility of
miRNA in differentiating PSC and CC by analysing the
serum miRNAs profile of PSC, CC and control subjects.
Materials and methods
Human subjects
Patients with CC (n5 70), PSC (n5 70) and healthy con-
trol (CTR) subjects (n5 70 with similar gender and age;
mean age 55 years, 60% male) were enrolled into this study
between 2008 and 2012. Clinical data of the enrolled
patients are summarized in Table 1. Liver biopsy was used
for staging of PSC (20 patients with histological stage I, 13
with stage II, 12 with stage III and 25 with stage IV).
Twenty patients with primary biliary cirrhosis (PBC) were
included as a disease control group that was not predis-
posed to the development of CC. The PBC patients
enrolled included 10 with early PBC and 10 with advanced
PBC, and 96% were positive to the anti-mitochondrial
antibody test (AMA). Diagnosis was conducted according
to European Association for the Study of the Liver (EASL)
Clinical Practice Guidelines 2009 [31]. The study protocol
was approved by the Institutional Review Board of Human-
itas Clinical and Research Centre, Rozzano (MI), Italy, and
all subjects gave written informed consent.
Peripheral blood samples were obtained and serum was
isolated by centrifugation at 1700 g for 15 min within 2 h
after blood collection. Serum was recovered, dispensed into
aliquots and stored at 2808C. Total RNA was extracted
from serum samples using the mirVana Paris isolation kit
(Ambion, Life Technologies, Carlsbad, CA, USA) specific
for liquid samples, and converted to cDNA by priming
with stem-looped RT primers (Human Megaplex RT pri-
mers; Life Technologies) combined with the TaqMan
VR
microRNA reverse transcription kit (Life Technologies).
miRNA quantification was performed with the microfluidic
card TaqMan
VR
Array (Life Technologies).
Study design
This study included two phases: (1) a discovery phase in
which differentially expressed miRNAs were selected from
profiling using high-throughput real-time polymerase
chain reaction (PCR); and (2) an independent validation
phase of miRNAs selected in the discovery phase. Each sub-
ject was assigned randomly to either discovery or validation
phase.
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In the discovery phase, we investigated the miRNA
expression profile in serum from 30 patients with CC, 30
with PSC and 30 CTR with similar gender and age. Ten
pools of three serum samples each (a total volume of 400
ll) were analysed for each group; 667 miRNAs were eval-
uated in each pool. The aim of this phase was to obtain a
specific profile of miRNA expression for each pathological
condition. In the validation phase all the miRNAs found to
be expressed differentially in CC and PSC were validated in
an independent cohort of 120 individual serum samples
(400 ll each), including 40 CTR, 40 PSC, and 40 CC with
similar gender and age (Table 1). A group of 20 patients
with PBC was used as the disease control group of auto-
immune cholestatic liver disease, which does not predis-
pose patients to the development of CC.
Extraction and quantification of circulating miRNAs
Total RNA was extracted from serum samples using the
mirVana Paris isolation kit (Ambion, Life Technologies)
specific for liquid samples by following the manufacturer’s
protocol for total RNA isolation, with minor modifications.
In brief, 400 ll of serum were denaturated by the addition of
an equal volume of 32 denaturing solution, followed by the
addition of 01 ng of a synthetic Caenorhabditis elegans
miRNA (Primm: oligos cel-miR-39, sequence UCACCGG-
GUGUAAAUCAGCUUG). This synthetic miRNAwas added
to each serum sample as an internal control for technical
variability of the RNA extraction process. Quantification of
cel-miR-39 by quantitative reverse transcription–PCR (qRT–
PCR) allows for the control of sample-to-sample differences
of RNA isolation efficiency, which is an important part of
our protocol, as we used a fixed volume of eluted RNA sam-
ples, rather than a fixed mass of input RNA as input for
qRT–PCR [30,32]. Total RNA extracted was converted to
cDNA by priming with two pools of stem-looped RT pri-
mers (Megaplex RT primers human pool A&B; Life Technol-
ogies) combined with the TaqMan
VR
microRNA reverse
transcription kit (Life Technologies). In brief, 3 ll of total
RNA was mixed with RT primer mix (310), deoxynucleoti-
des (dNTPs) with deoxythymidine triphosphate (dTTP)
(100 mM), multi-scribe reverse transcriptase (50 U/ll), RT
buffer (310), MgCl2 (25 mM), and RNase inhibitor (20U/
ll) in a total reaction volume of 75 ll. Thermal-cycling con-
ditions were as follows: 40 cycles at 168C for 2 min, 428C for
1 min and 508C for 1 s, followed by RT inactivation at 858C
for 5 min. The Megaplex RT product (25 ll) was pre-
amplified using the TaqMan PreAmp Master Mix (Life Tech-
nologies) and pre-amplification primers in a 25-ll PCR
reaction. For each pool of stemlooped RT primers in the
cDNA reaction, a different pool of PreAmp Primers (human
pool A&B; Life Technologies) was used. Thermal-cycling
conditions were as follows: 958C for 10 min, 558C for 2 min
and 758C for 2 min, followed by 12 cycles of 958C for 15 s
and 608C for 4 min.
MiRNA quantification was performed with the microflui-
dic card TaqMan
VR
Array Human MicroRNA Card Set ver-
sion 20 (Life Technologies), each containing 384 TaqMan
miRNA assays. The set enables accurate quantitation of 667
human miRNAs. All PCR reactions were performed on a
7900HT standard real-time PCR System (Life Technologies)
using the manufacturer’s recommended cycling conditions.
Differentially expressed miRNAs from the discovery
phase were validated in the validation phase using custom-
ized microfluidic cards designed specifically according to
our experimental design (Life Technologies). The following
criteria were applied for selection: absolute log2(fold
change)> 1, mean Ct< 30 and P< 005.
Table 1. Characteristics of patients with primary sclerosing cholangitis and cholangiocarcinoma
Primary sclerosing cholangitis All Discovery phase Validation phase
Patients 70 30 40
Gender (male) (%) 35 (50) 18 (60) 17 (43)
Age (years, mean) 45 48 43
Duration of disease (years6 SD) 17.56 5.3 18.56 9.6 16.56 7.2
Histological stages 3–4 (number) (%) 37 (52.9) 15 (50) 22 (55)
IBD (%) 4 (6) 2 (7) 2 (5)
UDCA (%) 66 (94.3) 28 (93.3) 38 (95)
Cholangiocarcinoma (%) 2 (3) 1 (3) 1 (2.5)
Cholangiocarcinoma All Discovery phase Validation phase
Patients 70 30 40
Gender (male) (%) 45 (64) 18 (60) 27 (68)
Age (years, mean) 64 64 65
Duration of disease (years6 SD) 1.46 0.5 1.06 0.5 1.86 0.3
Cirrhosis (number) (%) 46 (66) 21 (70) 25 (63)
Intrahepatic cholangiocarcinoma (%) 34 (48.6) 14 (46.7) 20 (50)
Primary sclerosing cholangitis (%) 7 (10) 6 (20) 1 (3)
Data are expressed as number (percentage) or mean6 standard deviation (s.d.). IBD5 inflammatory bowel disease; UDCA5ursodeoxycholic acid.
MicroRNAs and PSC
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Statistical analysis
For the discovery phase, Ct data were extracted using RQ
Manager Software version 121 and Data Assist Software ver-
sion 301, and imported into R. Quality control and statistical
analysis were performed using the package HTqPCR [33]. The
DCt was calculated using the mean of all expressed miRNAs
(Ct< 40) as reference, then relative quantities were calculated
as RQ5 2–DCt. Association with disease was evaluated with
a t-test on the DCt value. A miRNA was considered repre-
sented differentially if its absolute log2(fold change)> 1 and P-
value< 005 (t-test between two populations). Only miRNAs
that demonstrated an absolute log2(fold change)> 1, mean
Ct< 30 and P< 005 were selected for validation.
For the validation phase, RQs were calculated using as
reference the average Ct value of four endogenous controls
(miR-17, miR-29a, miR-30c and miR-30b), identified by
bioinformatic analysis (Supporting information and Sup-
porting information, Fig. S1). We modelled the disease out-
come as a function of the quantitative level of each miRNAs
independently (Supporting information, Table S1). A stand-
ard t-test was performed on log10(RQ) and the difference
was considered significant if P< 005. Odds ratio (OR) was
obtained with logistic regression for each mRNA. For an
alteration of a given miRNA in log scale, we obtained an OR
equal to the one indicated on each row and for each column.
The reference is the control group, or the PSC group when
comparing CC to PSC. The OR were filtered on the basis of
the corresponding P-value, considered significant if P< 005
(Supporting information, Table S2). For each miRNA, we
fitted a logistic model, and we extracted the coefficient
(beta) relative to the effect of the miRNAs. This coefficient
may be interpreted as the increase of log odds per unit
increase of log10(RQ) of each miRNA. The OR was calcu-
lated as OR5 ebeta. The P-value associated with each OR
was considered significant if P< 005. Receiver operating
characteristic (ROC) curves were obtained using logistic
regression, and the area under the curve (AUC) was calcu-
lated using the Epicalc package (R package version 21510).
To evaluate the discriminating effect of serum miRNAs,
ROC curves were established for each validated miRNA.
The AUC values were calculated from the logistic regres-
sion (Supporting information, Table S3). The results
revealed some miRNAs with large areas under the ROC
curve (AUC> 070) that are useful as biomarkers.
Results
Discovery phase: identification of disease-associated
miRNA candidates
In this study we analysed the miRNA profiling results with
the aim of identifying circulating miRNAs specific for PSC
and CC. A total of 667 miRNAs were evaluated in 10 pools
of three subjects for each group: PSC (n5 30), CC (n5 30)
and CTR subjects (n5 30). An average 219 of 667 miRNAs
were detected per sample (Supporting information, Fig. S2).
There were no differences detected among different stages,
consistent with the small number of samples at each stage.
We performed the following comparisons to obtain miR-
NAs signatures: (a) CC and PSC samples compared to CTR
samples to identify disease-correlated candidate miRNAs
deregulated in PSC and CC, (b) PSC compared to CTR
samples to identify PSC-associated candidate miRNAs, (c)
CC compared to CTR samples to extract CC-associated
candidate miRNAs and (d) CC compared to PSC samples.
Using the criteria illustrated in the Methods section
(Supporting information, Figs S3 and S4), we obtained a
list of candidate miRNAs (Fig. 1) which were carried for-
ward to the validation phase.
Validation phase: disease-associated miRNAs
Serum miRNAs identified in the discovery phase were vali-
dated using an independent cohort of PSC (n5 40), CC
(n5 40) and CTR subjects (n5 40). As stated above, we
used a single-subject serum sample for validation.
Similarly to the discovery phase, we compared (a) CC
and PSC (combined) to CTR samples, (b) PSC to CTR
samples, (c) CC to CTR samples and (d) CC to PSC.
Supporting information, Table S1 illustrates the miRNAs
included in the validation phase and corresponding P-value.
Using the criteria stated in the Methods section, we
found that miR-200c was down-regulated specifically in
PSC (P5 00001) (Fig. 2), whereas miR-483-5p and miR-
194 were up-regulated in CC when compared with CTR
(P< 00001 and P5 00099, respectively) (Fig. 3). Impor-
tantly, we also found that miR-222 and miR-483-5p were
up-regulated specifically in CC when compared with PSC
(P< 00011 and P5 00013, respectively) (Fig. 4). The
combined ROC analysis of identified miRNAs from each
disease group increases the AUC value significantly, sug-
gesting that the combination of these markers makes the
diagnosis even more specific and reliable.
We also observed up-regulation of miR-193b, miR-122
and miR-885-5p in PSC and CC compared with a healthy
control group (Supporting information, Fig. S5); these miR-
NAs have been reported to be altered in other liver diseases
and can be considered non-specific [34,35]. These results
were also confirmed by the analysis of PBC patients, an auto-
immune cholestatic liver disease that does not predispose
patients to the development of CC, because the expression of
the three miRNAs is also significantly different from that
seen in the CTR group (Supporting information, Table S4).
Discussion
The discovery of non-invasive specific biomarkers that can
be measured routinely in easily accessible samples and help
to diagnose PSC or CC is an unmet clinical need. In fact, to
F. Bernuzzi et al.
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Fig. 1. Deregulated miRNAs identified in the
discovery phase. (a) Deregulated miRNAs in
primary sclerosing cholangitis (PSC) and
cholangiocarcinoma (CC) relative to healthy
controls (CTR) were identified using a t-test
between PSC-CC and CTR (P< 005). The 183
miRNAs with Ct< 40 in> 50% samples per
group); (b) deregulated miRNAs in PSC relative
to CTR (t-test between 10 PSC and 10 CTR
(P< 005). The 172 miRNAs with Ct< 40
in> 50% samples per group); (c) deregulated
miRNAs in CC relative to CTR (t-test between
10 CC and 10 CTR (P< 005). The 184 miRNAs
with Ct< 40 in> 50% samples per group); (d)
deregulated miRNAs in CC relative to PSC (t-
test between 10 CC and 10 PSC (P< 005). The
177 miRNAs with Ct< 40 in> 50% samples per
group). The miRNAs that did not reach a
log2(fold change)> 1 are represented with a
lighter bar.
MicroRNAs and PSC
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date such diagnoses are not only difficult to achieve but
may remain uncertain, even after imaging and cytological
sampling have been attempted. The goal of this study was
to identify a panel of deregulated miRNAs in the serum
samples from these patients and to investigate their poten-
tial as biomarkers for detection and staging of disease;
indeed, the present work shows that specific patterns of
deregulated miRNAs are able to support each specific
diagnosis.
Cell-free miRNAs in body fluids are stable under harsh
conditions, including boiling, low/high pH, extended stor-
age and multiple freeze–thaw cycles [27,30,36]. Recently,
advances in studies of circulating miRNAs have led to the
concept that tissue- or organ-specific intracellular miRNAs
may be released into the circulation during cell death or
apoptosis owing to cell turnover, cellular destruction or
pathological injury. Therefore, miRNA profiles in serum
may, potentially, be used as biomarkers that could improve
diagnosis and the clinical management of diseases.
It is clear that chronic inflammatory common in choles-
tatic diseases are predisposing factors for CC [37,38]. It has
been found that miRNAs are involved in the pathogenesis
of CC, as specific miRNAs are either up-regulated [39] or
down-regulated [40,41]. The miRNAs in human bile have
been investigated for the purpose of identifying potential
CC biomarkers; however, bile samples were obtained by
endoscopic retrograde cholangiopancreatography, an inva-
sive procedure with associated complications [42].
To date, miRNA expression in serum and bile in PSC
and CC has been reported only in small cohorts, due per-
haps to the rarity of CC and PSC [29,43]. Voigtlander et al.
described a specific serum miRNA profile in a single pool
of six sera from patients with PSC and a single pool of six
sera from CC patients. Unfortunately, their small study is
also limited by the lack of data from any disease control
groups. In our study, we analysed PSC and CC as a single
pathological group with the aim of defining a specific bio-
marker to help in the diagnosis of PSC and CC. In addi-
tion, the use of PBC as a pathological control group
allowed us to confirm some well-known liver-specific miR-
NAs, such as as miR-122.
In this study, by profiling the serum miRNA expression
in PSC and CC, we showed a number of miRNAs deregu-
lated. In particular we have identified: (1) a PSC-associated
serum miRNA that can supplement the current diagnosis
of this disease; (2) a group of serum miRNAs associated
with CC that can be used for the diagnosis of this cancer;
(3) a serum miRNA that characterizes the evolution of PSC
to CC and, therefore, might allow a very early diagnosis in
individuals at risk of developing this dangerous cancer; and
finally, (4) a group of serum miRNAs altered in all diseases
studied, that can be considered non-specific. The analyses
of sera from patients with PBC suggest strongly the
disease-specificity of the identified serum miRNAs.
Some of the liver disease-associated miRNAs, miR-193b,
miR-122 and miR-885-5p, have already been described in
Fig. 2. miRNAs specifically deregulated in
primary sclerosing cholangitis (PSC)
samples compared to healthy controls
(CTR). (a) P-value relative to box-plot (b)
and odds ratio of single miRNA. (b)
miRNA levels in CTR, PSC and
cholangiocarcinoma (CC). Box-plots show
the minimum, median and maximum of
miRNA levels. A standard t-test was
performed, and a miRNA was considered
represented differently if absolute
log10(RQ)> 1 and P-value< 005. miR-200c
was down-regulated in PSC. (c) Receiver
operating characteristic (ROC) curve
analysis of miR-200c. Fraction of true
positive results (sensitivity) and false
positive results (1-specificity) for levels of
miRNA are shown. ROC curves were
obtained using logistic regression and the
area under the curve (AUC) was calculated
using the Epicalc package. AUC was
considered significant if> 070.
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the literature as expressed in the liver at the tissue and
serum level. These miRNAs emphasize an ongoing hepatic
pathological condition [34,35]. miR-885-5p and miR-122
are also up-regulated in hepatocellular carcinoma (HCC),
non-alcoholic fatty liver disease (NAFLD) and cirrhosis.
Their levels are correlated with fibrosis, steatosis and
inflammatory activity. In agreement with these previous
reports, our results showed an up-regulation of miR-122
and miR-885-5p. In fact, serum concentrations of these
miRNAs, together with miR-193b, were increased signifi-
cantly in all diseases studied including PSC, CC and PBC.
Importantly, in this study we identify PSC- and CC-
associated miRNAs as potential biomarkers. Indeed, miR-
200c may be used for diagnostic purposes, because there are
no PSC-specific serum markers available; similarly, miR-194
and miR-483-5p can allow the diagnosis of CC. Particular
attention should be paid to miR-222 and miR-483-5p,
which were both up-regulated in CC compared with PSC.
The combined use of miR-222 and miR-483-5p could be
used to monitor the course of PSC patients for early CC
detection. The validation as possible biomarkers of miR-
483-5p, up-regulated in CC compared with CTR and PSC is
very important. In contrast, miR-200c was down-regulated
in PSC compared with CTR and then up-regulated in CC
compared with PSC. Taken together, these results could be
important in diagnosis and patient monitoring, and could
identify an early development of the tumour.
Some limits of our work, however, need to be men-
tioned. First, due to the rarity of this disease, only a few of
the CC samples included in the study actually come from
Fig. 3. miRNAs deregulated specifically in
cholangiocarcinoma (CC) samples
compared to healthy controls (CTR).
(a) P-value relative to box-plot (b) and
odds ratio of single miRNA (b) miRNA
levels in CTR, primary sclerosing cholangitis
(PSC) and CC. Box-plots show the
minimum, median and maximum for
miRNA levels. A standard t-test was
performed and miRNA were considered
represented differently if absolute
log10(RQ)> 1 and P-value< 005. Two
miRNAs were identified: miR-483-5p and
miR-194, up-regulated in CC. (c) Receiver
operating characteristic (ROC) curve
analysis of single miRNA and ROC curve
analysis combined with the two altered
miRNA. Fraction of true positive results
(sensitivity) and false positive results (1-
specificity) for levels of miRNA are shown.
ROC curves were obtained using logistic
regression and the area under the curve
(AUC) was calculated using the package
Epicalc. AUC was considered significant
if> 070.
MicroRNAs and PSC
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PSC patients. A prospective study with a large cohort of
PSC patients is needed to validate the clinical use of these
markers. Secondly, some of the CC samples included were
intrahepatic CC developed in cirrhotic liver; even though it
is not clear if intra- and extrahepatic CC have a different
aetiology, it is known that liver cirrhosis itself predisposes
to cancer development. Finally, as a reflection of specific
characteristics of our tertiary referral centre, few PSC
patients in the current study have concomitant inflamma-
tory bowel diseases (IBD). This assures a more homogene-
ous study population but necessitates future studies on
patients with both PSC and IBD.
It is known that an inactivation of miR-200c results in
an induction of epithelial–mesenchymal transition,
whereas activation of miR-200c led to a reduction of epi-
thelial–mesenchymal transition, including a reduced cell
migration. Neural cell adhesion molecule 1 (NCAM1), a
known hepatic stem/progenitor cell marker, was demon-
strated to be a direct target of miR-200c [44]. Moreover,
Loo et al. described miR-483-5p as a robust endogenous
suppressor of liver colonization and metastasis [45]. It has
been shown that miR-194 targeted the 30-UTRs of several
genes that were involved in epithelial–mesenchymal transi-
tion and cancer metastasis [46]. These results support a
role for miR-194, which is expressed specifically in liver
parenchymal cells, in preventing liver cancer cell metastasis.
In addition, p53 activation also induces a significant
increase of miR-194 expression in tumour cell lines.
Fig. 4. Cholangiocarcinoma (CC)-associated
miRNAs in primary sclerosing cholangitis
(PSC). (a) P-value relative to box-plot (b)
and odds ratio of CC-associated miRNA in
PSC. (b) miRNA levels. The box-plot shows
the minimum, median and maximum of
miRNA levels. A standard t-test was
performed and miRNA were considered
represented differently if absolute
log10(RQ)> 1 and P-value< 005 (P-values
are shown in the table). Two miRNAs were
identified: miR-222 and miR-483-5p. (c)
Receiver operating characteristic (ROC)
curve analysis of CC-associated miRNAs
and ROC curve analysis combined with the
altered miRNAs. Fraction of true positive
results (sensitivity) and false positive results
(1-specificity) for levels of miRNA are
shown. ROC curves were obtained using
logistic regression, and the area under the
curve (AUC) was calculated using the
Epicalc package. AUC was considered
significant if> 070.
F. Bernuzzi et al.
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Considering the prominent role of p53 in preventing
metastasis, the induction of miR-194 by p53 may represent
a protective or self-controlling mechanism in tumour pro-
gression. Multiple miRNAs are also involved in the nuclear
factor kappa B (NF-jB) signalling pathway; for example,
miR-222 plays important inhibitory roles in cancer pro-
gression and may be a potential therapeutic target [47].
Special attention should be given to miRNAs deregulated
in CC in comparison to healthy controls and PSC patients.
Such a CC-associated marker deserves further study and
analysis. It would also be interesting to investigate further
the specific role of the miRNAs deregulated in PSC and in
CC in the pathogenesis of these diseases. The miRNAs
directly involved in PSC progression and CC development
could serve not only as specific biomarkers but also as
novel therapeutic targets.
Acknowledgements
This study was supported by grants from the Fondazione
Umberto Veronesi, Associazione Italiana per la Ricerca sul
Cancro (AIRC) and Programma Ricerca Indipendente –
Regione Lombardia, and partly by Dr Nicholas C. High-
tower, Centennial Chair of Gastroenterology from the Scott
and White Hospital, and the NIH grant DK07698 to G. A.
The supporting parties had no influence on the study
design, data collection and analyses, writing of the manu-
script, or the decision to submit the manuscript for
publication.
Disclosure
All authors have no disclosures to declare.
Role of each author
F. B. designed the experiments, wrote and edited the manu-
script and conducted statistical analysis. F. M. designed the
experiments, wrote and edited the manuscript and con-
ducted statistical analysis. A.L. performed the experiments,
wrote and edited the manuscript and conducted statistical
analysis. M. C., M. M., G. A., D. A., K. M. B., M. L. and G.
T. performed the experiments. L. R., F. P., X. S.-H. and G.-
X. Y. conducted statistical analysis. C. L. B. wrote and
edited the manuscript and conducted statistical analysis.
M. E. G. and P. I. designed the experiments and wrote and
edited the manuscript.
References
1 Yimam KK, Bowlus CL. Diagnosis and classification of primary
sclerosing cholangitis. Autoimmun Rev 2014; 13:445–50.
2 Williamson KD, Chapman RW. Primary sclerosing cholangitis.
Dig Dis 2014; 32:438–45.
3 Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME
et al. IgG4-associated cholangitis: a comprehensive review. Clin
Rev Allergy Immunol 2015; 48:198–206.
4 Beuers U, Gershwin ME. Unmet challenges in immune-
mediated hepatobiliary diseases. Clin Rev Allergy Immunol
2015; 48:127–31.
5 Folseraas T, Liaskou E, Anderson CA, Karlsen TH. Genetics in
PSC: what do the ‘risk genes’ teach us? Clin Rev Allergy Immu-
nol 2015; 48:154–64.
6 Tanaka A, Takikawa H. Geoepidemiology of primary sclerosing
cholangitis: a critical review. J Autoimmun 2013; 46:35–40.
7 Gatto M, Alvaro D. New insights on cholangiocarcinoma. World
J Gastrointest Oncol 2010; 2:136–45.
8 Angulo P, Lindor KD. Primary sclerosing cholangitis. Hepato-
logy 1999; 30:325–32.
9 Bergquist A, Ekbom A, Olsson R et al. Hepatic and extrahepatic
malignancies in primary sclerosing cholangitis. J Hepatol 2002;
36:321–7.
10 Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Inci-
dence and risk factors for cholangiocarcinoma in primary scle-
rosing cholangitis. Am J Gastroenterol 2004; 99:523–6.
11 Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM.
Impact of classification of hilar cholangiocarcinomas (Klatskin
tumors) on the incidence of intra- and extrahepatic cholangio-
carcinoma in the United States. J Natl Cancer Inst 2006; 98:
873–5.
12 Blechacz B, Gores GJ. Cholangiocarcinoma: advances in patho-
genesis, diagnosis, and treatment. Hepatology 2008; 48:308–21.
13 Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD.
Cholangiocarcinoma. Lancet 2005; 366:1303–14.
14 Alvaro D, Mancino MG, Glaser S et al. Proliferating cholangio-
cytes: a neuroendocrine compartment in the diseased liver. Gas-
troenterology 2007; 132:415–31.
15 Olnes MJ, Erlich R. A review and update on cholangiocarci-
noma. Oncology 2004; 66:167–79.
16 Alvaro D. Serum and bile biomarkers for cholangiocarcinoma.
Curr Opin Gastroenterol 2009; 25:279–84.
17 Bjornsson E, Kilander A, Olsson R. CA 19-9 and CEA are unre-
liable markers for cholangiocarcinoma in patients with primary
sclerosing cholangitis. Liver 1999; 19:501–8.
18 Charatcharoenwitthaya P, Enders FB, Halling KC, Lindor KD.
Utility of serum tumor markers, imaging, and biliary cytology
for detecting cholangiocarcinoma in primary sclerosing cholan-
gitis. Hepatology 2008; 48:1106–17.
19 Morris-Stiff G, Bhati C, Olliff S et al. Cholangiocarcinoma com-
plicating primary sclerosing cholangitis: a 24-year experience.
Dig Surg 2008; 25:126–32.
20 Nehls O, Gregor M, Klump B. Serum and bile markers for chol-
angiocarcinoma. Semin Liver Dis 2004; 24:139–54.
21 Patel T, Singh P. Cholangiocarcinoma: emerging approaches to
a challenging cancer. Curr Opin Gastroenterol 2007; 23:317–23.
22 Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R.
Serum tumor markers for the diagnosis of cholangiocarcinoma
in primary sclerosing cholangitis. Gastroenterology 1995; 108:
865–9.
23 Schulick RD. Primary sclerosing cholangitis: detection of cancer
in strictures. J Gastrointest Surg 2008; 12:420–2.
24 Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often
flanked by adenosines, indicates that thousands of human genes
are microRNA targets. Cell 2005; 120:15–20.
MicroRNAs and PSC
VC 2016 British Society for Immunology, Clinical and Experimental Immunology, 185: 61–71 69
25 Zhao M, Liu S, Luo S et al. DNA methylation and mRNA and
microRNA expression of SLE CD41 T cells correlate with dis-
ease phenotype. J Autoimmun 2014; 54:127–36.
26 Berrih-Aknin S. Myasthenia gravis: paradox versus paradigm in
autoimmunity. J Autoimmun 2014; 52:1–28.
27 Chen X, Ba Y, Ma L et al. Characterization of microRNAs in
serum: a novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res 2008; 18:997–1006.
28 Chin LJ, Slack FJ. A truth serum for cancer–microRNAs have
major potential as cancer biomarkers. Cell Res 2008; 18:983–4.
29 Brase JC, Wuttig D, Kuner R, Sultmann H. Serum microRNAs
as non-invasive biomarkers for cancer. Mol Cancer 2010; 9:306.
30 Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs
as stable blood-based markers for cancer detection. Proc Natl
Acad Sci USA 2008; 105:10513–8.
31 European Association for the Study of the Liver (AESL). EASL
Clinical Practice Guidelines: management of cholestatic liver
diseases. J Hepatol 2009; 51:237–67.
32 Kroh EM, Parkin RK, Mitchell PS, Tewari M. Analysis of circu-
lating microRNA biomarkers in plasma and serum using quan-
titative reverse transcription–PCR (qRT–PCR). Methods 2010;
50:298–301.
33 Dvinge H, Bertone P. HTqPCR: high-throughput analysis and
visualization of quantitative real-time PCR data in R. Bioinfor-
matics 2009; 25:3325–6.
34 Gui J, Tian Y, Wen X et al. Serum microRNA characterization
identifies miR-885-5p as a potential marker for detecting liver
pathologies. Clin Sci (Lond) 2011; 120:183–93.
35 Pirola CJ, Fernandez Gianotti T, Castano GO et al. Circulating
microRNA signature in non-alcoholic fatty liver disease: from
serum non-coding RNAs to liver histology and disease pathoge-
nesis. Gut 2015; 64:800–12.
36 Gilad S, Meiri E, Yogev Y et al. Serum microRNAs are promis-
ing novel biomarkers. PLoS One 2008; 3:e3148.
37 Alpini G, McGill JM, Larusso NF. The pathobiology of biliary
epithelia. Hepatology 2002; 35:1256–68.
38 Sirica AE. Cholangiocarcinoma: molecular targeting strategies
for chemoprevention and therapy. Hepatology 2005; 41:5–15.
39 Meng F, Henson R, Lang M et al. Involvement of human
micro-RNA in growth and response to chemotherapy in human
cholangiocarcinoma cell lines. Gastroenterology 2006; 130:
2113–29.
40 Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T. Epige-
netic regulation of microRNA-370 by interleukin-6 in malignant
human cholangiocytes. Oncogene 2008; 27:378–86.
41 Mott JL, Kobayashi S, Bronk SF, Gores GJ. Mir-29 regulates
Mcl-1 protein expression and apoptosis. Oncogene 2007; 26:
6133–40.
42 Li L, Masica D, Ishida M et al. Human bile contains
microRNA-laden extracellular vesicles that can be used for chol-
angiocarcinoma diagnosis. Hepatology 2014; 60:896–907.
43 Voigtl€ander T, Gupta SK, Thum S et al. MicroRNAs in serum
and bile of patients with primary sclerosing cholangitis and/or
cholangiocarcinoma. PLoS One 2015; 10:e0139305.
44 Oishi N, Kumar MR, Roessler S et al. Transcriptomic profiling
reveals hepatic stem-like gene signatures and interplay of miR-
200c and epithelial–mesenchymal transition in intrahepatic
cholangiocarcinoma. Hepatology 2012; 56:1792–803.
45 Loo JM, Scherl A, Nguyen A et al. Extracellular metabolic ener-
getics can promote cancer progression. Cell 2015; 160:393–406.
46 Meng Z, Fu X, Chen X et al. miR-194 is a marker of hepatic
epithelial cells and suppresses metastasis of liver cancer cells in
mice. Hepatology 2010; 52:2148–57.
47 Galardi S, Mercatelli N, Farace MG, Ciafre SA. NF-kB and c-
Jun induce the expression of the oncogenic miR-221 and miR-
222 in prostate carcinoma and glioblastoma cells. Nucleic Acids
Res 2011; 39:3892–902.
Supporting information
Additional Supporting information may be found in the
online version of this article at the publisher’s web-site:
Fig. S1. Cumulative distribution of the coefficient of vari-
ation shows the reduction of the variability after normal-
ization. The coefficient of variation (CV) was calculated
for miRNAs detected in all samples. Data presented in
the plot are either not normalized (RQ, grey line), nor-
malized with the arithmetic mean (NRQ_mean, yellow
line), geometric mean (NRQ_geomean, blue line) or with
four selected reference miRNA (NRQ_ref red line).
Fig. S2. (a) The miRNA population consists of more than
200 expressed miRNAs for each sample. On average, 219
miRNAs were detected per sample. (b) The mean and
median of Ct value for each pool before normalization.
Fig. S3. Analysis of pairwise raw Ct correlation. These
results indicate a good correlation among the data
because all the coefficients are higher than 80%, demon-
strating the reproducibility of the data. A grouping of all
the data along the straight line of slope equal to 1 and
passing through the origin in a graph showing the raw
values in Ct of the two samples being compared is con-
sistent with the high reproducibility of results. The more
the points are grouped along the bisector, the better is
the reproducibility. The distribution can be evaluated
through the assignment of an average correlation coeffi-
cient of the compared data: the closer the coefficient is to
the ideal value of 1, the better is the correlation. This
pairwise correlation analysis demonstrated overall satisfac-
tory quality and good reproducibility before normaliza-
tion and statistical testing.
Fig. S4. Data normalization. The mean Ct value of all
expressed miRNAs (Ct< 40) was used as the normaliza-
tion factor. The normalized data were properly centred,
confirming that part of the technical variability between
samples had been removed.
Fig. S5. Liver disease-associated miRNAs. (a) P-value rel-
ative to box-plot and odds ratio of liver disease-specific
miRNAs. (b) Liver disease-specific miRNA levels in
healthy controls (CTR), primary sclerosing cholangitis
(PSC) and cholangiocarcinoma (CC). Box-plots show the
minimum, median and maximum of miRNA levels. A
standard t-test was performed and a miRNA was consid-
ered differently represented if absolute log10 (RQ)> 1 and
P-value< 005 (P-values are shown in the table). Three
liver disease-specific miRNAs were identified: miR-193b,
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miR-122 and miR-885-5p, all up-regulated in PSC and
CC. (c) Receiver operating characteristic (ROC) curve
analysis by combination of the three miRNAs. Fraction of
true positive results (sensitivity) and false positive results
(1-specificity) for levels of miRNA are shown. ROC
curves were obtained using logistic regression and the
area under the curve (AUC) was calculated using the
package Epicalc. AUC was considered significant if> 070.
Table S1. Deregulated miRNAs included in the validation
phase and corresponding Pp-value. A standard t-test was
performed and data were considered significant if
P< 005.
Table S2. Odds ratio (OR) and P-value associated with
each miRNA. OR was obtained with logistic regression
for each miRNA. P-value was considered statistically sig-
nificant if P< 005.
Table S3. Area under curve (AUC) of each miRNA.
Table S4. Deregulated miRNAs analysed in sera from 20
PBC patients (10 early and 10 advanced) compared to
healthy control (CTR) subjects.
MicroRNAs and PSC
VC 2016 British Society for Immunology, Clinical and Experimental Immunology, 185: 61–71 71
